Trofosfamide

For research use only. Not for therapeutic Use.

  • CAT Number: R011319
  • CAS Number: 22089-22-1
  • Molecular Formula: C9H18Cl3N2O2P
  • Molecular Weight: 323.58
  • Purity: ≥95%
Inquiry Now

Trofosfamide(Cat No.:R011319)is an alkylating agent used in cancer therapy, primarily for treating various malignancies, including lymphoma and soft tissue sarcomas. It exerts its cytotoxic effects by introducing alkyl groups into the DNA, leading to cross-linking and subsequent disruption of DNA replication and transcription. This induces apoptosis in cancer cells. Trofosfamide is a prodrug, metabolized into its active form, which enhances its potency. Its ability to target rapidly dividing cells makes it an essential chemotherapeutic agent, though it requires careful monitoring due to potential toxicity and side effects.


Catalog Number R011319
CAS Number 22089-22-1
Synonyms

N,N,3-Tris(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-Oxide; ?Ixoten; NSC 109723; Trifosfamide; Trilofosfamida; Trilophosphamide; Triphosphamide; Trisfosfamide; Trophosphamide; Z 4828?

Molecular Formula C9H18Cl3N2O2P
Purity ≥95%
Target Bacterial
Storage -20°C
IUPAC Name N,N,3-tris(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine
InChI InChI=1S/C9H18Cl3N2O2P/c10-2-6-13-5-1-9-16-17(13,15)14(7-3-11)8-4-12/h1-9H2
InChIKey UMKFEPPTGMDVMI-UHFFFAOYSA-N
SMILES C1CN(P(=O)(OC1)N(CCCl)CCCl)CCCl
Reference

</br>1:Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide. Kroiss M, Deutschbein T, Schlötelburg W, Ronchi CL, Neu B, Müller HH, Quinkler M, Hahner S, Heidemeier A, Fassnacht M; German Adrenocortical Carcinoma Study Group..Horm Cancer. 2016 Jun;7(3):211-8. doi: 10.1007/s12672-016-0260-7. Epub 2016 Mar 9. PMID: 26961793 </br>2:Old wine in new pipes? Treatment of advanced non-small cell lung cancer with trofosfamide. Reißig A, Walther M.Onkologie. 2013;36(7-8):409-13. doi: 10.1159/000353544. Epub 2013 Jul 8. PMID: 23921759 </br>3:Partial response of metastatic mucosal melanoma after palliative chemotherapy with trofosfamide: a case report. Aigner B, Richtig E, Becker JC, Lingitz H, Marterer R, Niederkorn A, Ugurel S.J Clin Oncol. 2013 Jan 10;31(2):e31-2. doi: 10.1200/JCO.2012.44.2053. Epub 2012 Dec 3. No abstract available. PMID: 23213097 </br>4:Metronomic treatment with low-dose trofosfamide leads to a long-term remission in a patient with docetaxel-refractory advanced metastatic prostate cancer. Greiner J, Küfer R, Reske SN, Martin V, Döhner H, Ringhoffer M.Case Rep Med. 2010;2010:395720. doi: 10.1155/2010/395720. Epub 2010 Apr 11. PMID: 20396674 Free PMC Article</br>5:Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients. Atzpodien J, Morawek L, Fluck M, Reitz M.Cancer Chemother Pharmacol. 2009 Oct;64(5):901-5. doi: 10.1007/s00280-009-0939-3. Epub 2009 Feb 20. PMID: 19229537 </br>6:Ifosfamide or trofosfamide in patients with intraocular lymphoma. Jahnke K, Thiel E, Bechrakis NE, Willerding G, Kraemer DF, Fischer L, Korfel A.J Neurooncol. 2009 Jun;93(2):213-7. doi: 10.1007/s11060-008-9761-8. Epub 2008 Dec 20. PMID: 19099202 </br>7:A pilot study of docetaxel and trofosfamide as second-line /’metronomic/’ chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC). Görn M, Habermann CR, Anige M, Thöm I, Schuch G, Andritzky B, Brandl S, Burkholder I, Edler L, Hossfeld DK, Bokemeyer C, Laack E.Onkologie. 2008 Apr;31(4):185-9. doi: 10.1159/000118626. Epub 2008 Mar 20. PMID: 18418020 </br>8:Recurrent low- to intermediate-grade chondrosarcoma of the thumb with lung metastases: an objective response to trofosfamide. Debruyne PR, Dumez H, Demey W, Gillis L, Sciot R, Schöffski P.Onkologie. 2007 Apr;30(4):201-4. Epub 2007 Mar 23. PMID: 17396043 </br>9:Complete remission of relapsing high-grade angiosarcoma with single-agent metronomic trofosfamide. Kopp HG, Kanz L, Hartmann JT.Anticancer Drugs. 2006 Sep;17(8):997-8. PMID: 16940811 </br>10:Metronomic trofosfamide inhibits progression of human lung cancer xenografts by exerting anti-angiogenic effects. Klink T, Bela C, Stoelting S, Peters SO, Broll R, Wagner T.J Cancer Res Clin Oncol. 2006 Oct;132(10):643-52. Epub 2006 Jun 8. PMID: 16761121

Request a Quote